Comparative Pharmacology
Head-to-head clinical analysis: ULTRAVIST 240 versus ULTRAVIST 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ULTRAVIST 240 versus ULTRAVIST 300.
ULTRAVIST 240 vs ULTRAVIST 300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated nonionic contrast agent that attenuates X-rays by increasing the density of iodine atoms, enhancing vascular and tissue contrast during imaging procedures. It does not have intrinsic pharmacological activity.
Nonionic iodinated contrast medium that attenuates X-rays, providing vascular and tissue enhancement for imaging.
IV injection: 1.0-2.0 mL/kg (240 mg I/mL) for CT; total dose not to exceed 250 mL per procedure.
Intravenous: 1.0-2.0 mL/kg (300-600 mg iodine/kg) body weight; maximum 200 mL per procedure. Intra-arterial: varies by procedure.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged up to 10-30 hours, necessitating dose adjustment.
Terminal elimination half-life: 1.5-2 hours (normal renal function); prolonged in renal impairment (up to 10 hours in severe cases).
Primarily renal excretion via glomerular filtration; approximately >90% of the administered dose is excreted unchanged in the urine within 24 hours. Biliary/fecal excretion is negligible (<2%).
Renal: 95-100% as unchanged drug within 24 hours; biliary/fecal: <1%.
Category C
Category C
Radiographic Contrast Agent (Iodinated Non-Ionic)
Radiographic Contrast Agent (Iodinated Non-Ionic)